Adding a drug to improve blood flow in Alzheimer's treatment
Treatments studied
Part of Brain & nervous system, Hormones & metabolism, Mental health clinical trials.
This study tests whether a new medicine can improve blood vessel and insulin function in the brain while you continue your current Alzheimer's drug (lecanemab or donanemab). It may help the anti-amyloid therapy work better and slow down memory loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are fluent in English
- You have mild cognitive impairment or mild Alzheimer's disease, confirmed by a doctor
- You have had a positive test for amyloid plaques in the brain (via PET scan or spinal fluid)
- You have been on a stable dose of lecanemab or donanemab for at least 8 weeks
- You have a study partner (like a family member or friend) who can spend about 10 hours per week with you and help with the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called Lecanemab in people with early Alzheimer's. It uses a blood test to see how well the drug works. You may qualify if you have mild Alzheimer's or mild cognitive impairment due to Alzheimer's and have a positive amyloid test.
This study compares donanemab plus usual care to usual care alone for people with early Alzheimer's symptoms, to see how well donanemab works in everyday life. You may be able to join if you have early memory or thinking problems and have a brain scan or blood test showing Alzheimer's-related changes.
This study tests how lecanemab works in people with early Alzheimer’s, including those with mild dementia or mild memory problems. It aims to see if the drug can help clear brain plaques and slow down symptoms.
This trial tests whether galcanezumab, an antibody injection, can help people with mild-to-moderate Alzheimer's disease. It is for patients who have a confirmed Alzheimer's diagnosis and a caregiver who can support them.
This trial tests a drug called donanemab in people who have early signs of Alzheimer's disease (amyloid buildup in the brain) but are still thinking clearly. The goal is to see if the drug can slow or prevent cognitive decline before memory problems start.
This study looks at how well lecanemab works for people with early Alzheimer's disease. It aims to see if the drug can help slow down memory and thinking problems.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.